ABSTRACT
The current clinical management of RA favours a graduated stepup approach, in which a disease-modifying anti-rheumatic drug (DMARD), often methotrexate (MTX), is introduced early in order to achieve maximal suppression of inflammation with minimal delay. The dosage may be escalated gradually. Additional DMARDs or biologic agents may be introduced in combination.
